Quipazine is a piperazine drug used in scientific research. It is a serotonin reuptake inhibitor, and also a moderately selective serotonin receptor receptor agonist, binding to a range of different serotonin receptors, but particularly to the 5-HT2A and 5-HT3. It produces a head-twitch response in animal studies, but failed to produce psychedelic effects in humans at a dose of 25mg, which was the highest dose tested due to 5-HT3 mediated side effects of nausea and gastrointestinal discomfort. However Alexander Shulgin claimed that an effective psychedelic dose could be reached by blocking 5-HT3 receptors using a 5-HT3 antagonist.

Lisinopril/amlodipine, sold under the brand name Lisonorm among others, is a medication used to treat high blood pressure. It is a combination of lisinopril an ACE inhibitor with amlodipine a calcium channel blocker. It may be used when blood pressure is well controlled with each of the two agents alone. It is taken by mouth.
Lisinopril/amlodipine, sold under the brand name Lisonorm among others, is a medication used to treat high blood pressure. It is a combination of lisinopril an ACE inhibitor with amlodipine a calcium channel blocker. It may be used when blood pressure is well controlled with each of the two agents alone. It is taken by mouth. Side effects may include low blood pressure, kidney problems, liver problems, cough, and high blood potassium. It should not be used in people who have previously had angioedema due to ACE inhibitors. Use is not recommended during pregnancy or breastfeeding. Lisinopril works by decreasing angiotensin II and increasing bradykinin while amlodipine decreases the entry of calcium into the muscle cells in the heart and blood cells. The combination was approved for medical use in Europe in 2008. The combination is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. While it is available in India and Europe it is not available in Canada, Australia, or the United States as of 2019.